View Older Stories View More Recent Stories
-
Medicines Co. (MDCO) Provides Important Update on Ph 3 RNAi Program - Evercore ISI
-
ODYSSEY Results Seen as Positive for Medicines Co. (MDCO)
-
UPDATE: Evercore ISI Starts miRagen Therapeutics (MGEN) at Outperform
-
Jazz Pharmaceuticals (JAZZ) Xyrem Competitor Delayed - Evecore ISI
-
Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI
-
UPDATE: Evercore ISI Starts Dicerna Pharmaceuticals (DRNA) at Outperform; Alnylam Case Appears Favorable
-
Biogen (BIIB) Defended at Evercore ISI; BAN-2401 Data Should Not Move Stock
-
Mylan (MYL) Positioned for Possible Late 2019/2010 Launch of Glargine - Evercore ISI (SNY)
-
Evercore ISI Starts Apellis Pharmaceuticals (APLS) at Outperform
-
Valeant Pharma (VRX) in 'Very Good Shape' on Debt Covenants - Evercore ISI's Raffat
-
GSK (GSK) Not Trying to Break Price in HIV with Dulo, Positive for Gilead Sciences (GILD) - Evercore ISI Raffat
-
Everore ISI's Raffat Provides Takeaways on Juno Therapeutics (JUNO) ROCKET Trial Data (GILD)
-
Allergan (AGN) Should Be Up - Evercore ISI's Raffat
-
Teva Pharma (TEVA) Files Lawsuit Versus Eli Lilly (LLY) Related to CGRP Mab - Evercore ISI
-
Evercore ISI named #3 in U.S. Equity Research by Institutional Investor's All-America Equity Research Survey
-
UPDATE: Biogen (BIIB), Roche on Watch Amid Potential New PML case on Ocrevus
-
Too Much 'Confusion and Nervousness' in Allergan (AGN) - Evercore ISI
-
Express Scripts (ESRX) CMO Issues Blog on CAR-Ts and Gene Therapies
-
Allergan (AGN) Legal Move 'Extremely Important for Industry' - Evercore ISI Raffat
-
Evecore ISI's Raffat sees ~$29/sh valuation floor on Mylan (MYL) on the new guidance
-
Josh Schimmer Joins Evercore ISI Research Team
-
UPDATE: Evercore ISI Starts Dermira (DERM) at Outperform; Street Underestimating Acne Phase 3 Success
-
Valeant Pharma (VRX) Gains Tied to Speculation of Debt-for-Equity Swap - Evercore ISI's Raffat
-
Amgen (AMGN): ICER intends to lower the value-based price benchmark for Repatha - Evercore ISI
-
Gilead Sciences (GILD) Called 'Value Pick' at Evercore ISI
-
Valeant Pharma (VRX) is Soaring Because of This - Evercore ISI's Raffat
-
ASCO Abstract Titles Officially Available Online; Evecore ISI's Raffat Highlights a Few
-
Biogen (BIIB) Wins Interference versus Forward Pharma (FWP) - Evercore ISI
-
Valeant shares fall as Ackman exit highlights company's challenges
-
Pharma Stocks on Watch as Draft Obamacare Reform Bill Makes No Mention of Drug Prices - Evercore's Raffatt
-
Evercore ISI Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
Impax Laboratories (IPXL) Generic EpiPen Shows 'Meaningful Gains' Versus Mylan's EpiPen - Evercore ISI Raffat
-
Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
-
Valeant Pharma (VRX): 'Finally Some Good News' - Evecore ISI's Raffat
-
Allergan (AGN) on Watch After Raising Drug Prices
-
Allergan (AGN) Sees Sneaky Gains Into Year-End After Disastrous 2016
-
Allergan (AGN) Has an Important Catalyst Forthcoming that is Flying Under the Radar - Evercore ISI's Raffat
-
Medicines Co. (MDCO) Recovers; Evercore ISI's Raffat Says Data 'Looks Very Consistent and Durable'
-
Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's Raffat
-
Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI Raffat
-
Allergan CEO takes blame for big miss on quarterly earnings
-
Evercore ISI named # 3 in U.S. Equity Research by Institutional Investor's All-America Equity Research Survey
-
Valeant Pharma (VRX), Other Pharma Stocks Weaker as Clinton Op-Ed Discusses Measures on Drug Prices
-
Allergan (AGN) Namenda Concerns 'Not a Big Deal' - Evecore ISI's Raffat
-
Evercore ISI Raffat Highlights New Development on Teva Pharma (TEVA) from Copaxone Hearing
-
Mylan CEO to testify before House panel over EpiPen pricing
-
1997 CMS Letter to Mylan (MYL) Shows Evidence of EpiPen Medicaid Rebate - Evecore ISI's Raffat
-
Evercore ISI Starts Theravance Biopharma (TBPH) at Buy
-
Why All the Outcry About EpiPen Prices Now? It's Back to School Time
-
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore